No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer

doi:10.3748/wjg.v28.i38.5589

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 38

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4754)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

195

WORD

HTML

1789

Figures (1-4)

236

Tables (1-3)

225

Sum=2483

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

239

Download

590

Sum=829

Publishing Process of This Article

Item

Count

Browse

337

Download

1105

Sum=1442

Oct 14, 2022 (publication date) through Jan 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Oct 14, 2022; 28(38): 5589-5601
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589

Open in New Tab Full Size Figure Download Figure

Figure 1 Flowchart of the selection of gastric cancer patients. 5-FU: 5-fluorouracil; NSR: Non-sustained-release.

Open in New Tab Full Size Figure Download Figure

Figure 2 Univariate and Multivariate Cox analyses of prognostic factors of 5-year survival in this group. N stage (N0 and N1 vs N2 and N3), T stage (T1 and T2 vs T3 and T4), TNM stage (stage II and stage III), surgery type (Total gastrectomy vs Partial gastrectomy), Neoadjuvant therapy (No vs Yes) and Borrmann classification (Superficial Type, Type I and Type II vs Type III and Type IV) are the prognosis factor of gastric cancer patients.

Open in New Tab Full Size Figure Download Figure

Figure 3 Survival Outcomes in gastric cancer patients. A: Overall survival analysis in all gastric cancer patients; B: Overall survival analysis in stage II gastric cancer patients; C: Overall survival analysis in stage III gastric cancer patients. NSR: Non-sustained-release.

Open in New Tab Full Size Figure Download Figure

Figure 4 Survival analysis in the age and gender subgroups. A: Survival analysis in male gastric cancer patients; B: Survival analysis in female gastric cancer patients; C: Survival analysis in gastric cancer patients less than 60 years old; D: Survival analysis in gastric cancer patients is mor than 60 years old. NSR: Non-sustained-release.

Citation: Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5589